Advertisement Cumberland signs licensing deal for Acetadote and Caldolor in China - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cumberland signs licensing deal for Acetadote and Caldolor in China

Cumberland Pharmaceuticals has signed exclusive licensing agreement for Acetadote and Caldolor with Harbin Gloria Pharmaceuticals in China.

Acetadote (acetylcysteine) is injectable drug used to treat acetaminophen overdose, and Caldolor (ibuprofen) Injection is used to treat pain and fever in the hospital setting.

According to the agreement, Harbin Gloria gains exclusive rights to register and commercialize both the drugs in China.

Harbin Gloria will seek regulatory approval for the products in China, and would handle ongoing regulatory reporting, product marketing, distribution and sales in the territory following approval.

Cumberland is responsible for the intellectual property, product formulation, development and other supporting activities. The company will receive upfront and milestone licensing payments, as well as royalties on future sales of the drugs.

Cumberland CEO AJ Kazimi said the partnership with Harbin Gloria Pharmaceuticals expands the global presence of these products and improve the quality of care available to hospitalized patients in China.